Received Feb 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
vial of antigen of Shingrix had been reconstituted using the Arexvy's diluent and potentially administered to a patient; vial of antigen of Shingrix had been reconstituted using the Arexvy's diluent and potentially administered to a patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced wrong solution used in drug reconstitution (Verbatim: vial of antigen of Shingrix had been reconstituted using the Arexvy's diluent and potentially administered to a patient) and inappropriate dose of vaccine administered (Verbatim: vial of antigen of Shingrix had been reconstituted using the Arexvy's diluent and potentially administered to a patient). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 08-JAN-2025 Pharmacist called to inform that he suspected that a vial of antigen of Shingrix had been reconstituted using the Arexvy's diluent and potentially administered to a patient, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.